GYRE (Gyre Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by GYRE officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-04 | Claire Weston | Director | A | — | — |
| 2026-08-04 | Maxwell Kirkby | Director | A | — | — |
| 2026-06-22 | Weiguo Ye | Chief Operating Officer | MIXED | — | — |
| 2026-06-15 | Weiguo Ye | Chief Operating Officer | MIXED | — | — |
| 2026-06-11 | Weiguo Ye | Chief Operating Officer | MIXED | — | — |
| 2026-06-10 | Ying Luo | Chief Executive Officer | A | — | — |
| 2026-06-10 | Joshua Benjamin Bergmann | GC and Corporate Secretary | A | — | — |
| 2026-06-08 | Weiguo Ye | Chief Operating Officer | MIXED | — | — |
| 2026-05-27 | Weiguo Ye | Chief Operating Officer | MIXED | — | — |
| 2026-05-22 | Weiguo Ye | Chief Operating Officer | MIXED | — | — |
| 2026-05-20 | Ping Zhang | Director | D | — | — |
| 2026-05-20 | Weiguo Ye | Chief Operating Officer | MIXED | — | — |
| 2026-05-18 | Weiguo Ye | Chief Operating Officer | MIXED | — | — |
| 2026-05-07 | Ying Luo | Chief Executive Officer | Sell | — | — |
| 2026-05-06 | GNI USA, Inc. | 10%+ Owner | J | — | — |
| 2026-05-06 | Thomas Wilson Eastling | Chief Financial Officer | A | — | — |
| 2026-01-09 | Ping Zhang | Director | A | — | — |
| 2026-01-09 | Ruoyu Chen | Chief Financial Officer | A | — | — |
| 2025-08-26 | Dan Weng | Director | A | — | — |
| 2025-08-07 | Ping Zhang | Director | A | — | — |
| 2025-06-06 | Renate Parry | Director | A | — | — |
| 2025-06-06 | David M. Epstein | Director | A | — | — |
| 2025-06-06 | Thomas Wilson Eastling | Director | A | — | — |
| 2025-06-06 | Gordon Carmichael | Director | A | — | — |
| 2025-06-06 | Rodney L Nussbaum | Director | A | — | — |
| 2025-05-29 | Songjiang Ma | President | Sell | — | — |
| 2025-05-28 | Ping Zhang | Director | A | — | — |
| 2025-05-27 | Songjiang Ma | President | Sell | — | — |
| 2025-05-22 | Songjiang Ma | President | Sell | — | — |
| 2025-05-20 | Songjiang Ma | President | Sell | — | — |
| 2025-05-16 | Songjiang Ma | President | Sell | — | — |
| 2025-05-14 | Songjiang Ma | President | Sell | — | — |
| 2025-05-14 | Weiguo Ye | Chief Operating Officer | M | — | — |
| 2025-04-25 | Weiguo Ye | Chief Operating Officer | M | — | — |
| 2025-04-18 | Thomas Wilson Eastling | Director | M | — | — |
| 2025-03-25 | Songjiang Ma | President | Sell | — | — |
| 2025-03-21 | Songjiang Ma | President | Sell | — | — |
| 2025-03-19 | Songjiang Ma | President | Sell | — | — |
| 2025-03-17 | Songjiang Ma | President | Sell | — | — |
| 2025-03-13 | Songjiang Ma | President | Sell | — | — |
| 2025-03-11 | Weiguo Ye | Chief Operating Officer | A | — | — |
| 2025-03-11 | Songjiang Ma | President | Sell | — | — |
| 2025-03-07 | Songjiang Ma | President | Sell | — | — |
| 2025-03-05 | Songjiang Ma | President | Sell | — | — |
| 2025-03-03 | Songjiang Ma | President | Sell | — | — |
| 2025-02-27 | Songjiang Ma | President | Sell | — | — |
| 2025-02-25 | Songjiang Ma | President | Sell | — | — |
| 2025-02-21 | Songjiang Ma | President | Sell | — | — |
| 2025-02-19 | Songjiang Ma | President | Sell | — | — |
| 2025-02-14 | Songjiang Ma | President | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 64,005,887 | — |
| — | President | 2,806,642 | — |
| — | Chief Executive Officer | 2,575,362 | — |
| — | Chief Operating Officer | 703,000 | — |
| — | Chief Financial Officer | 15,000 | — |
| — | Director | 5,165 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the GYRE quote page; the site-wide leaderboard is on the insider transactions hub.